Since 2008, the European Bioanalysis Forum (EBF) has engaged its members and the broader bioanalytical community in discussions and surveys on the bioanalytical applications and challenges for dried blood spots (DBS). In 2011, EBF presented its Recommendation Paper on the validation of bioanalytical methods for DBS. In addition, EBF hosted separate symposia on DBS, or assigned sessions in the technology at its Open Symposia to ensure the connection of all scientists interested or involved. EBF also connected to an initiative within the International Consortium on Innovation and Quality in Pharmaceutical Development (IQ) to ensure synergy in the global discussions on DBS.

Bioanalysis and DBS became part of EBF’s agenda of EBF in June 2008 and have been repeatedly discussed ever since that first presentation in Basel. A full conference session was dedicated to DBS during the 2009 open EBF conference in Barcelona, and a 1.5-day workshop is currently in preparation.
Consortium History


Homepage http://www.europeanbioanalysisforum.eu/index.php

Points of Contact

Communication with EBF should be directed to the Steering Committee:
Margarete Brudny-Kloeppel, Bayer Schering Pharma AG, Germany
Arjen Companjen, Crucell, Netherlands
Michaela Golob, Merck-Serono, Germany
Philip Timmerman, Janssen Research & Development, Belgium
Peter van Amsterdam, Abbott Healthcare Products, Netherlands
Steve White, GSK, United Kingdom

The EBF Steering Committee can be mailed at info@europeanbioanalysisforum.eu
For financial/administrative matters use: admin@europeanbioanalysisforum.eu

EBF
website: http://www.europeanbioanalysisforum.eu
email: info@europeanbioanalysisforum.eu

Sponsors & Partners

Actelion Ltd
AstraZeneca
Boehringer Ingelheim
GlaxoSmithKline
Johnson & Johnson
Solvay Pharmaceuticals/Abbott